Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 3
1979 2
1980 4
1981 2
1982 2
1984 6
1985 6
1986 3
1987 1
1988 3
1989 6
1991 3
1992 5
1993 9
1994 5
1995 4
1996 4
1997 4
1998 2
1999 3
2000 10
2001 10
2002 16
2003 16
2004 25
2005 28
2006 46
2007 57
2008 52
2009 46
2010 54
2011 86
2012 95
2013 145
2014 170
2015 163
2016 187
2017 195
2018 230
2019 306
2020 314
2021 358
2022 455
2023 323

Text availability

Article attribute

Article type

Publication date

Search Results

3,069 results

Results by year

Filters applied: . Clear all
Page 1
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.
Liu Z, Zhao Y, Kong P, Liu Y, Huang J, Xu E, Wei W, Li G, Cheng X, Xue L, Li Y, Chen H, Wei S, Sun R, Cui H, Meng Y, Liu M, Li Y, Feng R, Yu X, Zhu R, Wu Y, Li L, Yang B, Ma Y, Wang J, Zhu W, Deng D, Xi Y, Wang F, Li H, Guo S, Zhuang X, Wang X, Jiao Y, Cui Y, Zhan Q. Liu Z, et al. Among authors: xi y. Cancer Cell. 2023 Jan 9;41(1):181-195.e9. doi: 10.1016/j.ccell.2022.12.004. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584672
A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis.
Xi Y, LaCanna R, Ma HY, N'Diaye EN, Gierke S, Caplazi P, Sagolla M, Huang Z, Lucio L, Arlantico A, Jeet S, Brightbill H, Emson C, Wong A, Morshead KB, DePianto DJ, Roose-Girma M, Yu C, Tam L, Jia G, Ramalingam TR, Marsters S, Ashkenazi A, Kim SH, Kelly R, Wu S, Wolters PJ, Feldstein AE, Vander Heiden JA, Ding N. Xi Y, et al. Cell Metab. 2022 Sep 6;34(9):1377-1393.e8. doi: 10.1016/j.cmet.2022.07.009. Epub 2022 Aug 19. Cell Metab. 2022. PMID: 35987202 Free article.
Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma Proteome Switch Mediating Monocyte/Macrophage Suppression.
Manta CP, Leibing T, Friedrich M, Nolte H, Adrian M, Schledzewski K, Krzistetzko J, Kirkamm C, David Schmid C, Xi Y, Stojanovic A, Tonack S, de la Torre C, Hammad S, Offermanns S, Krüger M, Cerwenka A, Platten M, Goerdt S, Géraud C. Manta CP, et al. Among authors: xi y. Circulation. 2022 Dec 6;146(23):1783-1799. doi: 10.1161/CIRCULATIONAHA.121.058615. Epub 2022 Nov 3. Circulation. 2022. PMID: 36325910 Free article.
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Cascone T, et al. Among authors: xi y. Nat Med. 2023 Mar;29(3):593-604. doi: 10.1038/s41591-022-02189-0. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928818 Free PMC article. Clinical Trial.
Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study.
Ni X, Li Z, Li X, Zhang X, Bai G, Liu Y, Zheng R, Zhang Y, Xu X, Liu Y, Jia C, Wang H, Ma X, Zheng H, Su Y, Ge M, Zeng Q, Wang S, Zhao J, Zeng Y, Feng G, Xi Y, Deng Z, Guo Y, Yang Z, Zhang J. Ni X, et al. Among authors: xi y. Lancet. 2022 Sep 24;400(10357):1020-1032. doi: 10.1016/S0140-6736(22)01541-0. Lancet. 2022. PMID: 36154677
SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr. Lu Z, et al. Among authors: xi y. J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471. J Clin Invest. 2022. PMID: 35642638 Free PMC article.
3,069 results